Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) is anticipated to post its results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
Galmed Pharmaceuticals Price Performance
NASDAQ:GLMD opened at $0.50 on Thursday. The company has a 50 day moving average price of $0.59 and a 200-day moving average price of $0.64. Galmed Pharmaceuticals has a 1-year low of $0.41 and a 1-year high of $2.09. The firm has a market cap of $2.77 million, a price-to-earnings ratio of -0.55 and a beta of 0.75.
Institutional Trading of Galmed Pharmaceuticals
A hedge fund recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 76.14% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Galmed Pharmaceuticals
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.
In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
